Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects.


Journal

Science translational medicine
ISSN: 1946-6242
Titre abrégé: Sci Transl Med
Pays: United States
ID NLM: 101505086

Informations de publication

Date de publication:
01 05 2019
Historique:
received: 18 08 2017
revised: 20 08 2018
accepted: 02 04 2019
entrez: 3 5 2019
pubmed: 3 5 2019
medline: 27 6 2020
Statut: ppublish

Résumé

Interference with immune cell proliferation represents a successful treatment strategy in T cell-mediated autoimmune diseases such as rheumatoid arthritis and multiple sclerosis (MS). One prominent example is pharmacological inhibition of dihydroorotate dehydrogenase (DHODH), which mediates de novo pyrimidine synthesis in actively proliferating T and B lymphocytes. Within the TERIDYNAMIC clinical study, we observed that the DHODH inhibitor teriflunomide caused selective changes in T cell subset composition and T cell receptor repertoire diversity in patients with relapsing-remitting MS (RRMS). In a preclinical antigen-specific setup, DHODH inhibition preferentially suppressed the proliferation of high-affinity T cells. Mechanistically, DHODH inhibition interferes with oxidative phosphorylation (OXPHOS) and aerobic glycolysis in activated T cells via functional inhibition of complex III of the respiratory chain. The affinity-dependent effects of DHODH inhibition were closely linked to differences in T cell metabolism. High-affinity T cells preferentially use OXPHOS during early activation, which explains their increased susceptibility toward DHODH inhibition. In a mouse model of MS, DHODH inhibitory treatment resulted in preferential inhibition of high-affinity autoreactive T cell clones. Compared to T cells from healthy controls, T cells from patients with RRMS exhibited increased OXPHOS and glycolysis, which were reduced with teriflunomide treatment. Together, these data point to a mechanism of action where DHODH inhibition corrects metabolic disturbances in T cells, which primarily affects profoundly metabolically active high-affinity T cell clones. Hence, DHODH inhibition may promote recovery of an altered T cell receptor repertoire in autoimmunity.

Identifiants

pubmed: 31043571
pii: 11/490/eaao5563
doi: 10.1126/scitranslmed.aao5563
pii:
doi:

Substances chimiques

Crotonates 0
Dihydroorotate Dehydrogenase 0
Hydroxybutyrates 0
Nitriles 0
Receptors, Antigen, T-Cell 0
Toluidines 0
teriflunomide 1C058IKG3B
Oxidoreductases Acting on CH-CH Group Donors EC 1.3.-
Electron Transport Complex III EC 7.1.1.8

Types de publication

Clinical Trial, Phase III Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Auteurs

Luisa Klotz (L)

University Hospital Münster, Department of Neurology with Institute of Translational Neurology, 48149 Münster, Germany. luisa.klotz@ukmuenster.de.

Melanie Eschborn (M)

University Hospital Münster, Department of Neurology with Institute of Translational Neurology, 48149 Münster, Germany.

Maren Lindner (M)

University Hospital Münster, Department of Neurology with Institute of Translational Neurology, 48149 Münster, Germany.

Marie Liebmann (M)

University Hospital Münster, Department of Neurology with Institute of Translational Neurology, 48149 Münster, Germany.

Martin Herold (M)

University Hospital Münster, Department of Neurology with Institute of Translational Neurology, 48149 Münster, Germany.

Claudia Janoschka (C)

University Hospital Münster, Department of Neurology with Institute of Translational Neurology, 48149 Münster, Germany.

Belén Torres Garrido (B)

University Hospital Münster, Department of Neurology with Institute of Translational Neurology, 48149 Münster, Germany.

Andreas Schulte-Mecklenbeck (A)

University Hospital Münster, Department of Neurology with Institute of Translational Neurology, 48149 Münster, Germany.

Catharina C Gross (CC)

University Hospital Münster, Department of Neurology with Institute of Translational Neurology, 48149 Münster, Germany.

Johanna Breuer (J)

University Hospital Münster, Department of Neurology with Institute of Translational Neurology, 48149 Münster, Germany.

Petra Hundehege (P)

University Hospital Münster, Department of Neurology with Institute of Translational Neurology, 48149 Münster, Germany.

Vilmos Posevitz (V)

University Hospital Münster, Department of Neurology with Institute of Translational Neurology, 48149 Münster, Germany.

Béatrice Pignolet (B)

CRC-SEP, Neurosciences Department, Toulouse University Hospital and INSERM U1043 - CNRS UMR 5282, Centre de Physiopathologie Toulouse-Purpan, Université Toulouse III, 31300 Toulouse, France.

Giulia Nebel (G)

University of Münster, Institute of Molecular Cell Biology, 48149 Münster, Germany.

Shirin Glander (S)

University of Münster, Department of Genetic Epidemiology, 48149 Münster, Germany.

Nicole Freise (N)

University of Münster, Department of Immunology, 48149 Münster, Germany.

Judith Austermann (J)

University of Münster, Department of Immunology, 48149 Münster, Germany.

Timo Wirth (T)

University Hospital Münster, Department of Neurology with Institute of Translational Neurology, 48149 Münster, Germany.

Graham R Campbell (GR)

University of Edinburgh, Centre for Clinical Brain Sciences, EH8 9YL Edinburgh, UK.

Tilman Schneider-Hohendorf (T)

University Hospital Münster, Department of Neurology with Institute of Translational Neurology, 48149 Münster, Germany.

Maria Eveslage (M)

University of Münster, Institute of Biostatistics and Clinical Research, 48149 Münster, Germany.

David Brassat (D)

CRC-SEP, Neurosciences Department, Toulouse University Hospital and INSERM U1043 - CNRS UMR 5282, Centre de Physiopathologie Toulouse-Purpan, Université Toulouse III, 31300 Toulouse, France.

Nicholas Schwab (N)

University Hospital Münster, Department of Neurology with Institute of Translational Neurology, 48149 Münster, Germany.

Karin Loser (K)

University Hospital Münster, Department of Dermatology, 48149 Münster, Germany.

Johannes Roth (J)

University of Münster, Department of Immunology, 48149 Münster, Germany.

Karin B Busch (KB)

University of Münster, Institute of Molecular Cell Biology, 48149 Münster, Germany.

Monika Stoll (M)

University of Münster, Department of Genetic Epidemiology, 48149 Münster, Germany.
Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, 6229 ER Maastricht, Netherlands.

Don J Mahad (DJ)

University of Edinburgh, Centre for Clinical Brain Sciences, EH8 9YL Edinburgh, UK.

Sven G Meuth (SG)

University Hospital Münster, Department of Neurology with Institute of Translational Neurology, 48149 Münster, Germany.

Timothy Turner (T)

Sanofi Genzyme, Cambridge, MA 02142, USA.

Amit Bar-Or (A)

Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

Heinz Wiendl (H)

University Hospital Münster, Department of Neurology with Institute of Translational Neurology, 48149 Münster, Germany.
Brain and Mind Centre, Medical Faculty, University of Sydney, Sydney, Camperdown, NSW 2050, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH